Liraglutide LL5 LL10 LL30 hot sale safe delivery HIGH purity product peptide
Pharmaceutical Grade
99%
shanghai
JL
box
2027-08-31
Peptide
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
Liraglutide LL5 LL10 LL30
Categories:
Research-
Class:
GLP-1 receptor agonist (acylated GLP-1 analog, 31-amino-acid peptide)
Status:FDA-approved (Victoza 2010, Saxenda 2014 for obesity)
Mechanism:A 31-amino-acid GLP-1 analog with a C16 fatty-acid chain (palmitoyl) attached to Lys26 via a gamma-glutamic acid spacer. This fatty-acid modification enables reversible binding to serum albumin, extending the half-life to ~13 hours and allowing once-daily dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.
EC50 (GLP1R Ec50):~10 nM
Source:DrugBank: DB06655; Knudsen LB, et al. J Med Chem. 2000;43(9):1664-1669.DOI
Clinical Development:FDA:Victoza, Saxenda (approved 2010-01-25)
References-
ChEMBL:
CHEMBL1213363
DrugBank:KEGG DRUG:PubChem:Disclaimer:Liraglutide is FDA-approved as a prescription medicine (Victoza for T2DM, Saxenda for obesity). This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Peptide
-
Location:
zhejiangshengjinhuashiyiwushijiangdongjiedaodongnanlu656hao
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
5-10
-
Year of Establishment:
2026
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product